Antipsychotic drugs for first-episode schizophrenia: A comparative review

CNS Drugs

Volumn 23, Issue 10, 2009, Pages 837-855

  Salimi, Kayvon ^a   Jarskog, L Fredrik ^b,c,d   Lieberman, Jeffrey A ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; CAUDATE NUCLEUS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; GRANULOCYTOSIS; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; MENSTRUAL IRREGULARITY; MYOCARDITIS; NEGATIVE SYNDROME; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; EPISODE OF CARE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 70349124929     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11314280-000000000-00000     Document Type: Review

References (97)

1. Jarskog LF, Gilmore JH. Neuroprogressive theories. In: Lieberman JA, Stroup TS, Perkins DO, editors. Textbook of schizophrenia. Washington, DC: American Psychiatric Publishing Inc., 2006: 137-150
2. Tohen M, Strakowski SM, Zarate Jr C, et al. The McLean- Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry 2000 Sep 15; 48 (6): 467-476
3. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004 Mar; 161 (3): 473-479
4. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000 Apr; 157 (4): 549-559
5. Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008 Jan; 69 (1): 106-113
6. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007 Nov; 68 (11): 1751-1762
7. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 Feb; 161 (2 Suppl.): 1-56
8. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004 Mar; 161 (3): 414-425
9. Hafner H, Maurer K, Loffler W, et al. Modeling the early course of schizophrenia. Schizophr Bull 2003; 29 (2): 325-340
10. Perkins DO, Gu H, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in firstepisode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005 Oct; 162 (10): 1785-1804
11. Drake RJ, Haley CJ, Akhtar S, et al. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry 2000 Dec; 177: 511-515
12. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005 Sep; 62 (9): 975-983
13. Lieberman JA, Fenton WS. Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 2000 Nov; 157 (11): 1727-1730
14. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 2007 Oct 1; 187 (7 Suppl.): S8-10
15. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-1223
16. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008 Mar 29; 371 (9618): 1085-1097
17. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, doubleblind 52-week comparison. Am J Psychiatry 2007 Jul; 164 (7): 1050-1060
18. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25 (4): 721-729
19. Merlo MC, Hofer H, Gekle W, et al. Risperidone, 2mg/day vs. 4mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 2002 Oct; 63 (10): 885-891
20. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003 Aug; 160 (8): 1396-1404
21. Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006 Sep; 86 (1-3): 234-243
22. Keefe RS, Seidman LJ, Christensen BK, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 2006 Jan 15; 59 (2): 97-105
23. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005 Apr; 62 (4): 361-370
24. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive firstepisode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003 May; 28 (5): 995-1003
25. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005 May; 162 (5): 947-953
26. Harvey PD, Rabinowitz J, Eerdekens M, et al. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005 Oct; 162 (10): 1888-1895
27. Robinson DG, Woerner MG, Napolitano B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006 Dec; 163 (12): 2096-2102
28. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007 Jul; 164 (7): 1061-1071 (Pubitemid 47121395)
29. Kahn RS, Fleischhacker WW, Boter H, et al. Are all antipsychotics equal? Author's reply to letter [letter]. Lancet 2008 Jul 19; 372 (9634): 202
30. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991 Aug; 48 (8): 739-745
31. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997 Aug; 17 (4): 308-313
32. Reilly JL,Harris MS, Keshavan MS, et al. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry 2006 Nov; 63 (11): 1189-1197
33. Lane HY, Chang WH, Chiu CC, et al. A pilot double-blind, dose-comparison study of risperidone in drug-naive, firstepisode schizophrenia. J Clin Psychiatry 2001 Dec; 62 (12): 994-995
34. Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a doubleblind clinical trial in first-episode patients. Harv Rev Psychiatry 1995 May; 3 (1): 1-9
35. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29 (1): 15-31
36. Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005 Mar; 162 (3): 495-506
37. Kurtz MM, Moberg PJ,Ragland JD, et al. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 2005 Jan; 31 (1): 167-174
38. Carpenter Jr WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988 May; 145 (5): 578-583
39. Kirkpatrick B, Fenton WS, Carpenter Jr WT, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006 Apr; 32 (2): 214-219
40. Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006 Dec; 88 (1-3): 5-25
41. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007 Jul; 33 (4): 1013-1022
42. Mayerhoff DI, Loebel AD, Alvir JM, et al. The deficit state in first-episode schizophrenia. Am J Psychiatry 1994 Oct; 151 (10): 1417-1422
43. Edwards J, McGorry PD, Waddell FM, et al. Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. Schizophr Res 1999 Nov 30; 40 (2): 147-158
44. Perkins DO, Gu H, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in firstepisode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005 Oct; 162 (10): 1785-1804
45. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002 Oct 1; 57 (2-3): 209-219
46. Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004 Jan; 161 (1): 116-124
47. Perkins DO, Johnson JL, Hamer RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006 Mar; 83 (1): 53-63
48. Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996 Apr; 53 (4): 313-319
49. Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003 Sep; 64 (9): 1075-1080
50. Gharabawi GM, Bossie CA, Zhu Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry 2006 May; 163 (5): 938-939
51. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 Suppl. 4: 8-13
52. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27 (2): 596-601
53. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005 Dec; 187: 537-543
54. McGlashan TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988; 14 (4): 515-542
55. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999 Sep 15; 46 (6): 729-739
56. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17 (2): 325-351
57. Addington J, Addington D. Cognitive functioning in first-episode schizophrenia. J Psychiatry Neurosci 2002 May; 27 (3): 188-192
58. Done DJ, Crow TJ, Johnstone EC, et al. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ 1994 Sep 17; 309 (6956): 699-703
59. Caspi A, Reichenberg A, Weiser M, et al. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 2003 Dec 15; 65 (2-3): 87-94
60. Kremen WS, Seidman LJ, Pepple JR, et al. Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr Bull 1994; 20 (1): 103-119
61. Hambrecht M, Lammertink M, Klosterkotter J, et al. Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry Suppl 2002 Sep; 43: s30-s37
62. Fuller R, Nopoulos P, Arndt S, et al. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 2002 Jul; 159 (7): 1183-1189
63. Blyler CR, Gold JM. Cognitive effects of typical antipsychotic treatment: another look. In: Sharma T, Harvey PD, editors. Cognitive deficits in schizophrenia. Oxford: Oxford University Press, 2000: 241-265
64. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25 (2): 201-222
65. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001 Feb; 158 (2): 176-184
66. Woodward ND, Purdon SE, Meltzer HY, et al. A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005 Sep; 8 (3): 457-472
67. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007 Jun; 64 (6): 633-647
68. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 2002 Jun 15; 51 (12): 969-971
69. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006 Feb; 163 (2): 185-194
70. Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Metaanalysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000 Jan; 157 (1): 16-25
71. Shenton ME, Dickey CC, Frumin M, et al. A review of MRI findings in schizophrenia. Schizophr Res 2001 Apr 15; 49 (1-2): 1-52
72. Nelson MD, Saykin AJ, Flashman LA, et al. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry 1998 May; 55 (5): 433-440
73. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003 Jan 25; 361 (9354): 281-288
74. Sun D, Phillips L, Velakoulis D, et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res 2009 Mar; 108 (1-3): 85-92
75. DeLisi LE, Sakuma M, Tew W, et al. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 1997 Jul 4; 74 (3): 129-140
76. Cahn W, Pol HE, Lems EB, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002 Nov; 59 (11): 1002-1010
77. Gur RE, Cowell P, Turetsky BI, et al. A follow-up magnetic resonance imaging study of schizophrenia: relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 1998 Mar; 55 (2): 145-152
78. Lieberman J, Chakos M, Wu H, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001 Apr 15; 49 (6): 487-499
79. Kasai K, Shenton ME, Salisbury DF, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 2003 Jan; 160 (1): 156-164
80. Chakos MH, Lieberman JA, Bilder RM, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994 Oct; 151 (10): 1430-1436
81. Keshavan MS, Bagwell WW, Haas GL, et al. Changes in caudate volume with neuroleptic treatment [letter]. Lancet 1994 Nov 19; 344 (8934): 1434
82. Doraiswamy PM, Tupler LA, Krishnan KR. Neuroleptic treatment and caudate plasticity. Lancet 1995 Mar 18; 345 (8951): 734-735
83. Chakos MH, Lieberman JA, Alvir J, et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995 Feb 18; 345 (8947): 456-457
84. Corson PW, Nopoulos P, Miller DD, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999 Aug; 156 (8): 1200-1204
85. Scheepers FE, de Wied CC, Hulshoff Pol HE, et al. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 2001 Jan; 24 (1): 47-54
86. Frazier JA, Giedd JN, Kaysen D, et al. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry 1996 Apr; 153 (4): 564-566
87. Chakos MH, Shirakawa O, Lieberman J, et al. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 1998 Oct 15; 44 (8): 675-684
88. Andersson C, Hamer RM, Lawler CP, et al. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology 2002 Aug; 27 (2): 143-151
89. Roberts RC. Effect of chronic olanzapine treatment on striatal synaptic organization. Synapse 2001 Jan; 39 (1): 8-15
90. Lee H, Tarazi FI, Chakos M, et al. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. Life Sci 1999; 64 (18): 1595-1602
91. Hokama H, Shenton ME, Nestor PG, et al. Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study. Psychiatry Res 1995 Nov 10; 61 (4): 209-229
92. Buchanan RW, Breier A, Kirkpatrick B, et al. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 1993 Jan; 150 (1): 59-65
93. Gur RE, Maany V, Mozley PD, et al. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998 Dec; 155 (12): 1711-1717
94. Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. J Clin Psychiatry 2006 Jun; 67 (6): 983-990 (Pubitemid 44049098)
95. Van Haren NE, Pol HE, Schnack HG, et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormallities in early adulthood. Biol Psychiatry 2008 Jan 1; 63 (1): 106-113
96. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000; 26 (1): 119-136
97. Cahn W, Van Haren NE, Hulshoff Pol HE, et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry 2006 Oct; 189: 381-382